empagliflozin vs ertugliflozin
Side-by-side comparison of empagliflozin and ertugliflozin Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Jardiance
Steglatro
Synjardy is a combination of two medicines, empagliflozin and metformin. It helps lower blood sugar in adults and children 10 years and older with type 2 diabetes, along with diet and exercise.
Steglatro is a drug that combines ertugliflozin and metformin. It helps lower blood sugar in adults with type 2 diabetes, along with diet and exercise.
Synjardy is used to improve blood sugar control in people with type 2 diabetes. It is for adults and children aged 10 years and older. Empagliflozin, one of the medicines in Synjardy, can also help reduce the risk of cardiovascular death in adults with heart disease. It can also lower the risk of heart failure and kidney problems in some adults.
Steglatro is used to help control blood sugar levels in adults with type 2 diabetes. You should use it along with a healthy diet and regular exercise. It is not for people with type 1 diabetes.
Empagliflozin helps your kidneys remove sugar from your blood through urine. Metformin lowers the amount of sugar your liver makes and helps your body use insulin better. Together, they help lower your blood sugar levels.
Steglatro contains two medicines. Ertugliflozin helps your kidneys remove sugar from your blood through urine. Metformin helps your body use insulin better and reduces sugar production in the liver.
- • Urinary tract infection
- • Yeast infection (in women)
- • Diarrhea
- • Nausea
- • Vomiting
- • Diarrhea
- • Nausea
- • Vomiting
- • Gas
- • Stomach discomfort
- Diabetic ketoacidosis 3,773
- Feeling sick to your stomach 3,212
- High blood sugar 3,043
- Diarrhea 2,806
- Weight loss 2,749
- Feeling sick to your stomach 86
- Problem with missing a dose 67
- Urinary tract infection 62
- Throwing up 59
- Fungal infection 58
Metformin, one of the drugs in Synjardy, can cause a serious side effect called lactic acidosis. This is a buildup of lactic acid in your blood. Get medical help right away if you have symptoms like weakness, muscle pain, trouble breathing, or stomach pain. Some people should not take Synjardy because of the risk of lactic acidosis. These include people with kidney problems, liver problems, or who drink a lot of alcohol.
Steglatro contains metformin, which can cause a serious side effect called lactic acidosis. This is a buildup of lactic acid in your blood. It can be life-threatening. Get medical help right away if you have symptoms like weakness, muscle pain, trouble breathing, stomach pain, or feel very sleepy.
Synjardy may harm your unborn baby, especially during the second and third trimesters. It is not recommended to use Synjardy while breastfeeding. Talk to your doctor if you are pregnant or plan to become pregnant.
Steglatro may harm your unborn baby, especially during the second and third trimesters. Breastfeeding is not recommended while taking Steglatro. Talk to your doctor if you are pregnant or plan to become pregnant.
Also Compare — Nearby Drugs
Compare empagliflozin with
Compare ertugliflozin with
How to Read This empagliflozin vs ertugliflozin Comparison
empagliflozin is classified in the SGLT2 Inhibitor drug class, while ertugliflozin sits within the SGLT2 Inhibitor class. Because both drugs share the same classification, they are often considered interchangeable in theory — but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, empagliflozin has 15,583 submissions while ertugliflozin has 332. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between empagliflozin and ertugliflozin — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.